Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Consulting agrmnt
Director departure
IDM PHARMA, INC. (IDMI) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/26/2009 8-K Quarterly results
05/18/2009 8-K Form 8-K -- Current report
05/11/2009 8-K Quarterly results
Docs: "IDM Pharma Reports First Quarter Financial Results"
04/13/2009 8-K Form 8-K -- Current report
03/31/2009 8-K Form 8-K -- Current report
03/09/2009 8-K Form 8-K -- Current report
02/26/2009 8-K Form 8-K -- Current report
12/18/2008 8-K Form 8-K -- Current report
12/15/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
11/18/2008 8-K Form 8-K -- Current report
11/13/2008 8-K Quarterly results
Docs: "IDM Pharma Reports Third Quarter Financial Results"
10/08/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Amendments to the Reg...
09/26/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "IDM Pharma Provides Update on Mifamurtide Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use"
08/07/2008 8-K Quarterly results
Docs: "IDM Pharma Reports Second Quarter Financial Results"
07/15/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
07/01/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "IDM Pharma Provides Update on Mifamurtide Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use"
06/27/2008 8-K Entry into a Material Definitive Agreement, Departure of Directors or Principal Officers; Election of Directors; Appointment ...
Docs: "IDM Pharma, Inc. 2000 Stock Plan, as amended"
06/12/2008 8-K Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
06/02/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide",
"IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated with Positive Survival Trend in Non-Small Cell Lung Cancer Patients"
05/16/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "IDM PHARMA ANNOUNCES PRESENTATIONS AT"
05/15/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "IDM Pharma Announces Updated Data From Mifamurtide Compassionate Access Program"
05/08/2008 8-K Quarterly results
Docs: "IDM Pharma Reports First Quarter Financial Results"
04/04/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
03/20/2008 8-K Quarterly results
Docs: "IDM Pharma Reports 2007 Financial Results",
"IDM Pharma Announces Availability of Mifamurtide through Compassionate Access Study"
02/06/2008 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
02/04/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "IDM Pharma Announces Phase 3 Mifamurtide Study Demonstrating Improved Survival Published in the"
01/30/2008 8-K Cost Associated with Exit or Disposal Activities
01/25/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use that Mifamurtide Provides a Possible Clinical Benefit in Survival"
01/15/2008 8-K Entry into a Material Definitive Agreement, Cost Associated with Exit or Disposal Activities, Departure of Directors or Princ...
12/31/2007 8-K Other Events, Financial Statements and Exhibits
Docs: "IDM Pharma Announces Termination of UVIDEM Development Collaboration and Expected Restructuring in Connection With Evaluation of Strategic Alternatives"
12/14/2007 8-K Other Events, Financial Statements and Exhibits
Docs: "IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company"
11/08/2007 8-K Quarterly results
Docs: "IDM Pharma Reports Third Quarter 2007 Financial Results"
11/02/2007 8-K Other Events, Financial Statements and Exhibits
Docs: "IDM Pharma Announces Data Presentation From Mifamurtide Compassionate Use Program",
"IDM Pharma Announces Updated Phase 2 UVIDEM",
"IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated with Positive Survival Trend in Lung Cancer Patients"
11/01/2007 8-K Other Events, Financial Statements and Exhibits
Docs: "IDM Pharma Announces Updated Phase 3 Mifamurtide Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy